Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | PRKACG | P22612 | 1/20 | 0.44 |
| ▸ | PRKACB | P22694 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8645691 | 0.82 | PRKACA (0.43) | PRKACAPRKACGPRKACBKDM4EGAA | |
| SCHEMBL31278209 | 0.82 | PRKACA (0.43) | PRKACAPRKACGPRKACBKDM4EGAA | |
| SCHEMBL13066533 | 0.80 | KDM4E (0.46) | PRKACAPRKACGPRKACBKDM4EGAA | |
| SCHEMBL4931757 | 0.79 | MAPK1 (0.50) | PRKACAPRKACGPRKACBMAPTMEN1 | |
| SCHEMBL10867779 | 0.79 | PRKACA (0.41) | PRKACAPRKACGPRKACBKDM4EGAA | |
| SCHEMBL31277953 | 0.77 | KDM4E (0.41) | PRKACAPRKACGPRKACBMAPTMEN1 | |
| SCHEMBL6542933 | 0.77 | PRKACA (0.40) | PRKACAPRKACGPRKACBMAPTKDM4E | |
| SCHEMBL26350852 | 0.77 | KDM4E (0.33) | PRKACAPRKACGPRKACBMAPTKDM4E | |
| SCHEMBL4758500 | 0.76 | MAPK1 (0.41) | PRKACAPRKACGPRKACBMAPTMEN1 | |
| SCHEMBL6249863 | 0.74 | MAPT (0.47) | PRKACAPRKACGPRKACBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118948864-A | Composition for relieving stomach ache from lilac flower, preparation and application thereof | 内蒙古农业大学 | 2024-11-15 | — | — | CN | claimed |
| US-20030134862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-07-17 | — | — | US | claimed |
| WO-2003053976-A1 | PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR | BIOVITRUM AB (SE) | 2003-07-03 | — | — | WO | claimed |
| CN-118948864-A | Composition for relieving stomach ache from lilac flower, preparation and application thereof | 内蒙古农业大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024085725-A1 | NOVEL COMPOUND DERIVATIVE AND PHARMACOLOGICAL USE THEREOF | 고려대학교 산학협력단 | 2024-04-25 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| EP-1720545-B1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7985288-B2 | Colorant compound and ink including the colorant compound | CANON KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7985288-B2 | Colorant compound and ink including the colorant compound | CANON KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| WO-1996034916-A2 | INK COMPOSITION | ZENECA LIMITED (GB) | 1996-11-07 | — | — | WO | disclosed |
| WO-1995033724-A1 | PHENETHANOLAMINE DERIVATIVES AND THEIR USE AS ATYPICAL BETA-ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1994026260-A1 | METHODS AND COMPOUNDS FOR INHIBITING CELL PROLIFERATIVE DISORDERS CHARACTERIZED BY ABNORMAL abl ACTIVITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 46 Jabotinsky Street (IL) | 1994-11-24 | — | — | WO | disclosed |
| EP-0245222-B1 | NITRILOPHORIC ELECTRON-DONOR-ACCEPTOR-ADSORBENTS | GELINNOVATION H.B. (SE) | 1990-07-04 | — | — | EP | disclosed |
| US-4897467-A | ELECTRON DONOR-ACCEPTOR ADSORPTION; HYDROPHILIC POLYMER NETWORK WITH LIGANDS CONTAINING NITRILE GROUPS | GELINNOVATION H.B. (SE) | 1990-01-30 | — | — | US | disclosed |
| EP-0245222-A2 | Nitrilophoric Electron-Donor-Acceptor-adsorbents | GELINNOVATION H.B. (SE) | 1987-11-11 | — | — | EP | disclosed |
| US-4236005-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134862-A1 | Compounds | PPARG, PPARA, PPARD | PRKACA 1533/4885PRKACG 1188/4885PRKACB 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.